skip to main content

Niraparib Fatigue Management — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

EasyGynaecological CancersNiraparib Fatigue ManagementSCE Medical Oncology

A 55-year-old woman with ovarian cancer on niraparib develops grade 3 fatigue significantly limiting her self-care. What is the management?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: D — Hold niraparib until fatigue improves to ≤grade 1, then resume at a REDUCED dose (300→200 mg, or 200→100 mg) — fatigue is one of the most common dose-limiting toxicities of PARP inhibitors

PARP inhibitor fatigue management: hold for grade 3+, resume at reduced dose when ≤grade 1. Niraparib dose levels: 300→200→100 mg. Exclude other fatigue causes (anaemia, thyroid, depression). Exercise is the strongest evidence-based intervention for cancer-related fatigue alongside dose modification.

Reference: BNF Niraparib; NOVA; ESMO Supportive Care